DataMeds AI MEDS
DataMeds AI Q2 FY26: revenue $1.8M, down 77%; diluted EPS −$7.13
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001493152-26-038581
Key figures from this report
These are the numbers DataMeds AI reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$1.8M−77% from $7.8M in Q2 FY2510-Q income statement, on EDGAR
- Net income−$18.4MAgainst −$6.7M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$7.13Against −$0.11 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$2.5M+485% from $420K in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations−$2.9MAgainst −$2.1M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 5122 and related industry codes: the same peer list as the financial tables.
- Sharing Services Global SHRG
- Cosmos Health COSM public float $10M, Jun 30, 2025
- Stemtech STEK public float $6M, Jun 30, 2025